- Department / Institute
- Division of Transfusion Medicine, Cell Therapeutics, and Hemostaseology, University Hospital of the LMU Munich
- Subject area
- Experimental Cell Therapy
- Project title
- Development of improved lentiviral CAR-T vectors for cell therapy
- Name of supervisor
- PD Dr. med. Christian Wichmann
- Number of open positions
- 1
- Language requirements
- Proficiency in English
- Academic requirements
- Master's Degree
- Project time plan
- Full Doctoral Study-Model: 36 or 48 months
- Contact
- csc.international@lmu.de
Project description
The adoptive cell transfer of antigen-receptor-modified T-lymphocytes/T-cells (Car-T-cells) is a new component of cancer immunotherapy. The patient's own (autologous) T-lymphocytes are obtained by apheresis. They are then provided with a viral vector (a so-called gene shuttle) with the help of which a gene (the CAR) is introduced into the T cells. This gene recognizes a specific cell surface antigen, e.g. B. CD19 on malignant B cells, and induces cell death of the CD19-positive tumor cells. In addition to the desired anti-tumor effect, however, the procedure has some very dangerous side effects such as uncontrolled cytokine release. New, controllable vectors are intended to make these side effects manageable.